Transparent Drug Pricing Act of 2019
Bill journey · stage 2 of 5
Under committee review
What it doesSummary introduced in senate (Apr 1, 2019)
Transparent Drug Pricing Act of 2019
This bill establishes several requirements relating to the prices of prescription drugs.
For example, state Medicaid drug-use review programs must require pharmacists to disclose an individual's out-of-pocket cost for a prescription drug, and the price without health insurance, at the point-of-sale. Additionally, health insurers must publish the co-payment amount for each covered prescription drug prior to the annual open-enrollment period.
The bill also temporarily prohibits the retail list price of drugs and biologics from exceeding the lowest retail list price among Canada, France, the United Kingdom, Japan, or Germany.
What just happenedApr 1, 2019
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Who’s behind it
- Introduced in SenateApr 1, 2019
- Apr 1, 2019IntroReferral
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Health, Education, Labor, and Pensions Committee - Apr 1, 2019IntroReferral10000
Introduced in Senate